VEGF Trap-Eye Phase 2 trial reports significant improvement in neovascular disease

Regeneron Pharmaceuticals, Inc and Bayer HealthCare AG has announced the result of Phase 2 trial of the VEGF Trap-Eye. It reported to have achieved durable improvements in visual acuity and in biologic measures of neovascular disease, including retinal thickness and active choroidal neovascularization lesion size.

Full article »

Ocular diseases can be cured by new drug - VEGF Trap-Eye

vegf-trap-eyeLatest study proves that particular dose of new drug named "VEGF Trap-Eye" on an as-needed basis can cure devastating ocular diseases.

Full article »

Protected by Comment Guard Pro